Epsilon Healthcare Ltd (EPN)

EPN Chart

vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Advanced

Show News Mov Avgs 9-day 10-day 20-day 30-day 50-day 100-day 150-day 200-day Mov Avgs 9-day 21-day 30-day 200-day Simple Exponential Weighted Simple Exponential Weighted vs Index S&P/ASX 20 S&P/ASX 50 S&P/ASX 100 S&P/ASX 200 S&P/ASX 300 All Ordinaries Small Ordinaries All Technology Consumer Staples Energy Financials Health Care Industrials Info Technology Materials Real Estate Comm. Services Utilities

Mov Avgs 10-day 20-day 30-day 50-day 100-day 150-day 200-day 9/21 Cross 10/30 Cross Golden Cross Vol RSI BB

Day 3m 6m 1yr 5yr 10yr

EPN's Principal Activity is the the Group plans to be a worldwide manufacturer and distributor of hydroponics equipment, materials and nutrients; and leader in the development and delivery of medicinal cannabis.

Announcements

Company Overview

Dividend History

Directors & Management

Name	Title	Since	Bio
Mr Philip Leighfield	Joint Company Secretary	Sep 2020
Mr Jarrod Travers White	Chief Financial Officer,Interim Chief Executive Officer	May 2020
Mr Sonny Didugu	Joint Company Secretary,Chief Operating Officer	May 2020
Mr Lou Anthony Cattelan	Non-Executive Director	Mar 2018	Mr Lou Anthony Cattelan Non-Executive Director Mr Cattelan has experience in the pharmaceutical, nutraceutical, complementary healthcare, and allied health industry sectors with over 30 years experience across a range of operational and strategic areas including, quality assurance, supply chain management, new product development, TGA and FDA regulatory compliance, sales and marketing, business development, and special projects. He has sat on the Consumer Healthcare Products Australia Committee for Complementary Medicines as a key liaison between TGA and industry stakeholders. He has now retired as Head of Sales and Marketing of Contract Pharmaceutical Services of Australia (CPSA). In this role over the past 19 years, he has consulted all Pharma companies including Pfizer, MSD, Mylan and GSK to take innovative concepts through to compliant finished products. He has also worked in senior hands-on positions with Ella Bache, Milpharma, Sunspot Products, Bayer Pharma and Blackmores. He is a member of Risk Committee.
Mr Steven Xiaobo XU	Non-Executive Director	Jan 2018	Mr Steven Xiaobo XU Non-Executive Director Mr Xu is the Managing Director of Une-Innovation Consulting Australia Pty Ltd and Founding Partner of INP Capital Inc which manages a series of venture capital funds. The venture capital funds invest in companies specialised in Medical/Healthcare, AI, Fintech and Industrial technology and Medical Cannabis across Australia, New Zealand, North America and Israel. He has over 15 years experience working at PricewaterhouseCoopers and listed companies in Australia and China. He specialises in financing, IPO and M&A activities in a range of sectors. He is the Chairman of the Strategy and Management Committee (from 4 June 2019) and Risk Committee.
Mr Alan Preston Beasley	Non-Executive Director,Non-Executive Deputy Chairman	Aug 2016	Mr Alan Preston Beasley Non-Executive Director,Non-Executive Deputy Chairman Mr Beasley has worked in the Investment Banking and Investment Management industries for over 30 years with Bankers Trust Australia, Goldman Sachs Asset Management, and BNP Paribas Asset Management Ltd. The last two positions as Managing Director and Australian Country Head. He is a director and former director of several listed and unlisted public and private companies including two public charities. He has experience in assisting to bring innovative and new technology companies to market, especially in the Health and Life Sciences sectors. He is the Chairman of Risk Committee and a member of Strategy and Management Committee (from 4 June 2019).
Jarrod White	Chief Financial Officer	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
20/07/20	Lou Cattelan	Buy	+83,334	$0.30	$25,000	Participation in share purchase plan
10/07/20	Alan Beasley	Transfer	100,000	$0.30	$30,000	Off-market transfer
10/07/20	Alan Beasley	Transfer	780,000	$0.30	$234,000	Off-market transfer

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Lou Cattelan	20/07/2020	N/A	327,803	N/A	N/A
Steven XU	20/07/2020	243,334	1,587,302	N/A	N/A
Alan Beasley	10/07/2020	0	880,000	N/A	N/A

Show All

Top 20 Shareholders About the Data

Name	Shares	Capital
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>	3,760,299	2.67%
Agri Fibre Industries Pty Ltd	2,627,375	1.87%
MMR Corporate Services Pty Ltd	2,500,000	1.78%
Citicorp Nominees Pty Limited	2,114,534	1.50%
Mr George Daaboul	2,000,000	1.42%
Mr Nicholas Charles Deverell Pownall	1,979,929	1.41%
Mrs Katja Gordon	1,865,000	1.32%
UNE-Innovation Consulting Australia Pty Ltd	1,587,302	1.13%
Pears Daisley Pty Ltd <Daisley Pears A/C>	1,500,000	1.07%
Sawfam Pty Ltd <Sawyer Super Fund A/C>	1,409,751	1.00%
HSBC Custody Nominees (Australia) Limited	1,141,518	0.81%
Madonna Andrews <Andrews Family A/C>	1,023,810	0.73%
IECO Industries Pty Ltd	962,625	0.68%
Hamsar Pty Ltd	950,000	0.67%
Pegasus Agriculture Pty Ltd	944,810	0.67%
Mr Sid Bainy and Mrs Samia Bainy	900,000	0.64%
Blackies Super Holdings Pty Limited <Amanda's Super Fund A/C>	900,000	0.64%
Johnpenn Super Pty Ltd <Hall Superannuation Fund A/C>	800,000	0.57%
Mrs Margaret Doreen Beehag	780,000	0.55%
CS Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C>	744,324	0.53%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

EPN Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.